
International Journal For Multidisciplinary Research
E-ISSN: 2582-2160
•
Impact Factor: 9.24
A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal
Home
Research Paper
Submit Research Paper
Publication Guidelines
Publication Charges
Upload Documents
Track Status / Pay Fees / Download Publication Certi.
Editors & Reviewers
View All
Join as a Reviewer
Get Membership Certificate
Current Issue
Publication Archive
Conference
Publishing Conf. with IJFMR
Upcoming Conference(s) ↓
WSMCDD-2025
GSMCDD-2025
AIMAR-2025
Conferences Published ↓
ICCE (2025)
RBS:RH-COVID-19 (2023)
ICMRS'23
PIPRDA-2023
Contact Us
Plagiarism is checked by the leading plagiarism checker
Call for Paper
Volume 7 Issue 4
July-August 2025
Indexing Partners



















Exploring Triphala's Therapeutic Potential: Targeting AD Pathology Proteins BACE1, GSK3β, and MMP9 through InSilico Approaches
Author(s) | Mr. Somdeb Bhattacharya, Dr. Sujoy Ghosh |
---|---|
Country | India |
Abstract | Alzheimer's disease (AD) and associated dementia have emerged as prominent global health concerns over recent decades. Characterized by complex genetic, epigenetic, and metabolomic alterations, AD remains incurable. Extensive exploration into the genetic landscape of AD pathology has led to the identification of several biomarkers strongly implicated in the disease, including GSK3ß, BACE1, and MMP9, alongside the hallmark APP and Tau-related neurofibrillary tangle formation. While certain commercially available drugs such as memantine and donepezil are utilized in AD treatment, their efficacy is subject to debate, with notable side effects. Consequently, attention has turned to Ayurvedic herbal components, frequently consumed in India, renowned for their diverse health benefits and comparatively lower adverse effects. In this investigation, Triphala, a composite formulation comprising extracts from Emblica officinalis, Terminalia chebula, and Terminalia bellerica, was selected for the study. Through identification of the bioactive constituents of these plant extracts, molecular docking analyses were conducted with GSK3ß, BACE1, and MMP9 proteins. Findings indicate that the bioactive constituents of Triphala exhibit enhanced interactions with these target proteins, suggesting a potential improvement in AD pathology through Triphala consumption. However, it is imperative to underscore that further molecular experimentation in laboratory settings is essential to validate these initial findings conclusively. Looking ahead, the composition of Triphala holds promise as a prospective therapeutic agent for the treatment of AD-associated dementia. |
Keywords | Alzheimer’s Disease (AD), Triphala, Biomarkers, GSK3ß, BACE1, MMP9, Emblica officinalis, Terminalia chebula, Terminalia bellerica, APP, moleculer docking |
Field | Biology > Genetics / Molecular |
Published In | Volume 7, Issue 4, July-August 2025 |
Published On | 2025-08-04 |
Share this

E-ISSN 2582-2160

CrossRef DOI is assigned to each research paper published in our journal.
IJFMR DOI prefix is
10.36948/ijfmr
Downloads
All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.
